Companies in #Central Nervous System Disorders

Formation Bio is an AI-native drug development company building a clinical-stage pipeline through in-licensing and asset acquisition, with a focus on using technology and AI to accelerate clinical trial execution. In early 2026, the company launched a new subsidiary, Kenmare Bio, to develop a miR-124 inhibitor licensed from a Chinese partner for inflammatory diseases.

Omeros Corporation is a Seattle-based biopharmaceutical company developing small-molecule and biologic therapies for complement-mediated diseases, immune-related disorders, and central nervous system conditions. Its first commercial product, Yartemlea (narsoplimab), is the first FDA-approved treatment for transplant-associated thrombotic microangiopathy (TA-TMA) in hematopoietic stem cell transplantation.